Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
Explore this paper's citation graph
Summary
In postmenopausal women with osteoporosis, raloxifene increases bone mineral density in the spine and femoral neck and reduces risk of vertebral fracture and was associated with a lower incidence of breast cancer.
- Type
- article
- Published
- 1999-08-18
- Cited by
- 2,870
- References
- 36
- OpenAlex
- https://openalex.org/W2112629831
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:12191884
Keywords
Medicine, Raloxifene, Osteoporosis, Selective estrogen receptor modulator, Placebo
References
- Long-term estrogen replacement therapy prevents bone loss and fractures.
- Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group.
- Measurement of serum osteocalcin with a human‐specific two‐site immunoradiometric assay
- Dual X‐ray absorptiometry quality control: Comparison of visual examination and process‐control charts
- Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
- Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens.
- The Association of Radiographically Detected Vertebral Fractures with Back Pain and Function: A Prospective Study
- Hormone replacement therapy and risk of venous thromboembolism: population based case-control study
- Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
- Comparative calibration without a gold standard.
- Use of a low-literacy patient education tool to enhance pneumococcal vaccination rates. A randomized controlled trial.
- Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women
- Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis
- Transection of the oesophagus for bleeding oesophageal varices
- Relationship of Bone Turnover to Bone Density and Fractures
- Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
- The influence of clinical variables on hospital costs after orthotopic liver transplantation.
- Endometrial fluid accumulation in asymptomatic postmenopausal women
- Risk of venous thromboembolism in users of hormone replacement therapy.
- Immunoassay for quantifying type I collagen degradation products in urine evaluated.
Cited by
- Bisphosphonat (Risedronat) plus Kalzium in der Osteoporosetherapie — Ein Beitrag zu mehr Wirtschaftlichkeit? Eine Untersuchung aus gesundheitsökonomischer Sicht
- Therapy for fracture prevention.
- Mechanism of action of estrogens and selective estrogen receptor modulators.
- Assessment of bone quality, quantity, and turnover with multiple methodologies at multiple skeletal sites.
- Aromatase Inhibitors and Inactivators for Breast Cancer Therapy
- Post-menopausal osteoporosis.
- Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study.
- Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis.
- Evaluation of bone mineral density in inflammatory bowel disease: current safety focus.
- Relationship Between Changes in Bone Mineral Density and Fracture Risk Reduction With Antiresorptive Drugs: Some Issues With Meta‐Analyses
- Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women
- Calcium supplement and osteoporosis medication use in women and men with recent fractures
- Raloxifene and Vitamin K2 Combine to Improve the Femoral Neck Strength of Ovariectomized Rats
- The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers.
- Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6‐Month Double‐Blind Placebo‐Controlled Trial
- Where are we with postmenopausal hormone therapy in 2005?
- Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture
- Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.
- Effects of raloxifene on insulin sensitivity, beta-cell function, and hepatic insulin extraction in normal postmenopausal women.
- [Factors affecting quality of care for elderly subjects undergoing surgery for hip fracture: review of the literature].
Related papers
- Growth Inhibition of Human Uterine Leiomyoma Cells by Selective Estrogen Receptor Modulator
- Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
- [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
- [Clinical experience with raloxifene].
- In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators.
- Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
- Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus.
- Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator.
- [Estrogen, SERM].